PATENT CLAIM ANALYSIS

Application Number: 15744278
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "134100"]

Abstract:
Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.

Claim (Index 14):
A composition for treating diseases caused by neovascularization, comprising the fusion polypeptide of  claim 1 , wherein\n a VEGF receptor-specific peptide of the fusion polypeptide is non-covalently bound to a VEGF receptor to inhibit neovascularization.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.31034
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14917460', '14740194', '12789215', '14740158', '14442376']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6830350891812973
- 35 USC 102 Novelty (BERT): 0.5206133873768249
- Combined Prediction Score: 0.66679291900085
- Mean Citation Score: 259.111848
- Max Citation Score: 305.7306
- Similarity Product: 229.78402933666703

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test